Keyword Search
 
2018 | 2017
DateTitle 
08/07/18Aileron Therapeutics Reports Second Quarter 2018 Financial Results
Preclinical in-vivo ALRN-6924 combination data with CDK4/6 inhibitors, PD-1/-L1 inhibitors, or paclitaxel (formulated as Abraxane or Taxol) all show promise in breast cancer and other cancer models Initiation of clinical trials of ALRN-6924 in combination with approved anti-cancer drugs planned over the next six to twelve months Recent publications in Science Translational Medicine, Nature Communications, and The Hematologist–ASH News and Reports reflect increased scientific recognition ... 
Printer Friendly Version
08/02/18Aileron Therapeutics to Present at the Canaccord Genuity 38th Annual Growth Conference
CAMBRIDGE, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq:ALRN), the leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced that Manuel Aivado, SVP and Chief Medical Officer, will present at the Canaccord Genuity 38th Annual Growth Conference being held in Boston, MA. Presentation Details: Event:       Canaccord Genuity 38th Annual Growth Conference Date:         Thursday, August 9, 2018 ... 
Printer Friendly Version
07/31/18Aileron Therapeutics to Report Second Quarter 2018 Financial Results on August 7, 2018
CAMBRIDGE, Mass., July 31, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq:ALRN), the leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced that the Company will report its second quarter 2018 financial results on Tuesday, August 7, 2018 after the close of market. About Aileron Aileron is a clinical-stage biopharmaceutical company advancing stapled peptides, a novel class of therapeutics for cancers and other diseases. Stapled peptides a... 
Printer Friendly Version
05/29/18Aileron Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference
CAMBRIDGE, Mass., May 29, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq:ALRN), the leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced that Manuel Aivado, CMO and CSO, will present at the Jefferies 2018 Global Healthcare Conference being held in New York, NY. Presentation Details: Event: Date: Time: Location:         Jefferies 2018 Global Healthcare Conference Tuesday, June 5, 2018 2:00 p.m. EDT New York, N... 
Printer Friendly Version
05/22/18Aileron Therapeutics Announces Publication of ALRN-6924 Nonclinical Data in T-cell Lymphomas by Researchers at Dana-Farber Cancer Institute
Data published in Nature Communications show MDM2 and MDMX are targetable vulnerabilities within TP53-wild-type T-cell Lymphomas CAMBRIDGE, Mass., May 22, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq:ALRN), the leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced the publication of nonclinical results in Nature Communications demonstrating the anti-cancer potential of ALRN-6924 in models of T-cell lymphoma (TCL). ALRN-6924 is designed to... 
Printer Friendly Version
05/15/18Aileron Therapeutics Announces Changes to Management
CAMBRIDGE, Mass., May 15, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq:ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced that Joseph A. Yanchik III has resigned as President and Chief Executive Officer of the Company and as a member of its Board of Directors. Biopharma industry veteran John P. Longenecker, Ph.D. has been named interim Chief Executive Officer. “I would like to thank Joe on behalf of the Boar... 
Printer Friendly Version
05/09/18Aileron Therapeutics Reports First Quarter 2018 Financial Results
CAMBRIDGE, Mass., May 09, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq:ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today reported business highlights and financial results for the first quarter ended March 31, 2018. “In the first quarter, we continued to advance our clinical and non-clinical stapled peptide programs as we pursue our mission to provide transformational outcomes for patients with life-threatening disea... 
Printer Friendly Version
04/11/18Aileron Therapeutics Announces Publication by Researchers at Albert Einstein College of Medicine of ALRN-6924 Nonclinical Data in Acute Myeloid Leukemia
Nonclinical data featured in Science Translational Medicine show dual inhibition of MDM2 and MDMX restored p53 function and demonstrated strong response rates in AML model CAMBRIDGE, Mass., April 11, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced the publication of nonclinical results in Science Translational Medicine demonstrating the anti-cancer potential of A... 
Printer Friendly Version
04/02/18Aileron Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
Encouraging interim clinical results from studies of ALRN-6924 and progress against new programs support advancement and expansion of portfolio development plan CAMBRIDGE, Mass., April 02, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2017. “2017 was a pivotal ye... 
Printer Friendly Version
03/28/18Aileron Therapeutics Announces Expansion of Scientific Advisory Board
Drs. Druker, List and Prives join Aileron’s pioneering efforts to advance its stapled peptide approach to restoring p53’s cancer-fighting function   CAMBRIDGE, Mass., March 28, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced that three leading oncology experts have joined its Scientific Advisory Board (SAB).    “We are honored that world-class scientists and p... 
Printer Friendly Version
03/19/18Aileron Therapeutics Appoints Jeffrey A. Bailey to its Board of Directors
CAMBRIDGE, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stapled peptides developing therapeutics for cancers and other diseases, today announced the appointment of Jeffrey A. Bailey as Chairman of its Board of Directors. Mr. Bailey brings more than 30 years of leadership experience in the healthcare industry across multiple functional areas including R&D, business development, finance and commercial operations. He c... 
Printer Friendly Version